Project Grant R15GM152890
- The University of Utah was awarded a $2,117,500 Project Grant under the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) to conduct research on "Xenobiotic Induction Mechanisms Affecting Pharmacokinetics and Pharmacodynamics Among Medically Complex Children, Adolescents, and Young Adults." The project aims to better understand factors influencing drug safety and efficacy in medically complex patients experiencing...
- This $475,670 CAREER Project Grant awarded by the National Science Foundation's Division of Chemical, Bioengineering, Environmental, and Transport Systems (CFDA 47.041) aims to develop a new method for tracking molecular changes in live tissue over time. The project will focus on creating a nanostructure-based system to continuously monitor cellular activity and interactions, which can help improve understanding of cellular behavior and advance medical treatments, particularly for complex...
- This Project Grant from the National Science Foundation's Mathematical and Physical Sciences Directorate provides $500,000 to Eastern Illinois University to develop peroxisome targeting chemical technologies and tools. Under the award, Professor Beck and his students will adapt peroxisome targeting peptide sequences to create modular moieties that can direct small molecule cargoes to peroxisomes. They intend to characterize these peroxisome interaction moieties to assess cell permeability,...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is intended to support the development and validation of a chemically induced dimerization (CID) system capable of detecting nanomolar concentrations of coenzyme A (CoA) in the presence of excess acetyl-CoA. This CID system is being created to provide a universal assay method for screening histone acetyltransferases, which are important...
- The National Institute of General Medical Sciences (NIGMS) awarded a $467,947 Project Grant to the University of Colorado-Denver under CFDA 93.859 (Biomedical Research and Research Training program) to create bioinformatics tools that facilitate identifying genetic variants contributing to adverse drug reactions (ADRs). The key products to be delivered include: 1) A protein docking server to assess how drug variants could cause potential side effects, and 2) Online tools to identify specific...
- This Project Grant awarded by the National Science Foundation (NSF) under the Engineering program (CFDA 47.041) provides $450,000.00 to the University of Texas at Austin over the period of January 1, 2025 to December 31, 2027. The project aims to develop novel biosensing tools for therapeutic drug monitoring, specifically for the antipsychotic medication clozapine. The key products and services to be delivered include: Selection and optimization of DNA/RNA aptamers that bind strongly and...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $421,600 to The Morgridge Institute for Research, Inc. to understand how metabolic conditions influence the behavior of human cells. The key products and services to be delivered under this 5-year award include: Elucidating genetic and environmental contributions to human cell fitness and growth, leveraging innovative tools such as a...
- This $224,088 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to develop high-throughput microfluidic technology for studying enzyme function using non-canonical amino acids. The project will leverage the High-Throughput Microfluidic Enzyme Kinetics (HT-MEK) platform developed at Stanford University to enable the parallel expression, purification, and quantitative assay...
- The National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), has awarded a $529,359 Project Grant to Kennesaw State University to advance the development of next-generation deep eutectic solvents (DES) for biomedical applications. The project aims to improve the preservation and stabilization of protein- and enzyme-based drugs and products by investigating the nanostructure and properties of DES and their impact on...
- This $360,320 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop and test the first continuous electrochemical sensors for monitoring large protein and peptide analytes, such as insulin and cardiac markers. The project, titled "Aptamer Tagging with Redox Quenchers: A Critical Breakthrough in the Sensitivity of...
CHEMICAL BIOLOGY APPROACHES TO UNDERSTAND INTERINDIVIDUAL VARIABILITY IN CARBOXYLESTERASE ACTIVITY - PROJECT SUMMARY - MICHAEL W. BECK, EASTERN ILLINOIS UNIVERSITY BEFORE AN ORALLY DELIVERED DRUG CAN REACH ITS TARGET IN THE BODY IT MUST FIRST BE ABSORBED BY THE DIGESTIVE SYSTEM AND PASS THROUGH THE LIVER VIA THE HEPATIC PORTAL SYSTEM. DURING THIS PROCESS, THE DRUG IS METABOLIZED BY ENZYMES IN THESE TISSUES. THIS METABOLISM CONTROLS THE BIOAVAILABILITY OF ORAL DRUGS; THUS THE ACTIVITY AND EXPRESSION LEVELS OF THESE ENZYMES IS IMPORTANT. HUMAN CARBOXYLESTERASES (CESS) ARE HIGHLY EXPRESSED IN THE INTESTINES AND THE LIVER AND THEREFORE PLAY A KEY ROLE IN CONTROLLING THE METABOLISM OF MANY DRUGS. THE OVERALL ACTIVITY OF CESS, HOWEVER, CAN BE DRASTICALLY DIFFERENT FROM PERSON TO PERSON. THIS INTERINDIVIDUAL VARIABILITY HAS BEEN SHOWN TO INFLUENCE THE METABOLISM AND, IN SOME CASES, CLINICAL OUTCOMES OF PATIENTS TREATED WITH DRUGS THAT ARE SUBSTRATES FOR CARBOXYLESTERASE 1 (CES1). THE FACTORS THAT CONTRIBUTE TO CES1 ACTIVITY VARIATION HAVE NOT BEEN FULLY UNCOVERED, DESPITE THE ESTABLISHED IMPORTANCE OF CES1 IN DRUG METABOLISM. WE BELIEVE THIS LACK OF KNOWLEDGE IS DUE TO THE SCARCITY AND LIMITATIONS OF CURRENTLY AVAILABLE APPROACHES TO STUDY CES1 ACTIVITY IN LIVE SAMPLES. TO ADDRESS THESE CHALLENGES, THIS PROPOSAL AIMS TO DEVELOP AND OPTIMIZE FLUOROGENIC PROBES THAT CAN SPECIFICALLY REPORT ON CES1 ACTIVITY IN LIVE SAMPLES. THESE PROBES WILL BE DEPLOYED TO GENERATE CHEMICAL BIOLOGY-BASED APPROACHES THAT CAN RAPIDLY EVALUATE SMALL MOLECULES FOR THEIR POTENTIAL TO INTERFERE WITH CES1 ACTIVITY AND DETERMINE THE INFLUENCE OF CES1 GENETIC POLYMORPHISMS ON CES1 ACTIVITY. THE PROBES AND METHODS CREATED IN THIS PROPOSAL WILL ENABLE RAPID ANALYSIS OF CES1 ACTIVITY UNDER DIFFERENT CONDITIONS IN LIVE CELLS. THE APPLICATION OF THESE APPROACHES TO STUDY FACTORS THAT INFLUENCE CES1-MEDIATED DRUG METABOLISM WILL REVEAL NEW RISK FACTORS FOR INEFFECTIVE TREATMENT WITH CES1-SUBSTRATE DRUGS. OVERALL, THE STUDIES PROPOSED HERE UNCOVER FACTORS THAT MODULATE CES1 ACTIVITY RESULTING IN SAFER AND MORE EFFECTIVE TREATMENTS WITH CES1-SUBSTRATE DRUGS WHILE PROVIDING AN EXCELLENT TRAINING PLATFORM FOR UNDERGRADUATE STUDENTS IN MODERN BIOMEDICAL RESEARCH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $355.2k | 2/1/24 |